Sidley’s representation of Tricida Inc.’s Chapter 11 filing has been named “Healthcare/Life Sciences Deal of the Year (Between $100MM - $500 MM)” at The M&A Advisor Awards 2023. The annual awards program recognizes excellence in dealmaking by honoring the firms and professionals “whose activities set the standard for the M&A industry.”
Sidley acted as lead counsel for the debtor in the Chapter 11 protection filing of Tricida Inc., a clinical-stage pharmaceutical company focused on the goal of slowing the progression of chronic kidney disease through the treatment of metabolic acidosis by an investigational drug candidate, Veverimer. Tricida filed for Chapter 11 protection on January 11, 2023 in the Bankruptcy Court for the District of Delaware. The filing lists US$100–US$500 million in liabilities, including approximately US$200 million in principal funded debt under its convertible notes.
The team was led by Restructuring partners Sam Newman (Los Angeles) and Charles Persons (Dallas), with Corporate partners Geoff Levin and Chaim Theil (both New York) and Litigation partners Sara Brody and Sarah Hemmendinger (both San Francisco).
Sidley acted as lead counsel for the debtor in the Chapter 11 protection filing of Tricida Inc., a clinical-stage pharmaceutical company focused on the goal of slowing the progression of chronic kidney disease through the treatment of metabolic acidosis by an investigational drug candidate, Veverimer. Tricida filed for Chapter 11 protection on January 11, 2023 in the Bankruptcy Court for the District of Delaware. The filing lists US$100–US$500 million in liabilities, including approximately US$200 million in principal funded debt under its convertible notes.
The team was led by Restructuring partners Sam Newman (Los Angeles) and Charles Persons (Dallas), with Corporate partners Geoff Levin and Chaim Theil (both New York) and Litigation partners Sara Brody and Sarah Hemmendinger (both San Francisco).